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Abstract: Caribbean sponges of the genus Smenospongia are a prolific source of chlorinated secondary
metabolites. The use of molecular networking as a powerful dereplication tool revealed in the
metabolome of S. aurea two new members of the smenamide family, namely smenamide F (1) and G
(2). The structure of smenamide F (1) and G (2) was determined by spectroscopic analysis (NMR, MS,
ECD). The relative and the absolute configuration at C-13, C-15, and C-16 was determined on the basis
of the conformational rigidity of a 1,3-disubstituted alkyl chain system (i.e., the C-12/C-18 segment of
compound (1). Smenamide F (1) and G (2) were shown to exert a selective moderate antiproliferative
activity against cancer cell lines MCF-7 and MDA-MB-231, while being inactive against MG-63.
Keywords: Smenospongia aurea; marine natural products; structure elucidation; anti-tumor lead
molecules; smenamides; solid tumor cell lines; conformational analysis
1. Introduction
Marine organisms are a source of compounds with enormous chemical diversity, which, in turn,
translates to a wide variety of biological activities. Many marine natural products show unusual and
unique chemical structures, often containing halogen atoms. Halogenated natural products are widely
present in nature. Currently, more than 5000 compounds are reported in the literature and most of
them have a marine origin [1,2].
Our research program, aimed at discovering new bioactive compounds from marine organisms,
focused in recent years on the metabolome of Caribbean sponges of the genus Smenospongia, which have
proven to be very rich in new chlorinated secondary metabolites. Among them are smenamides [3],
smenothiazoles [4] and conulothiazoles [5], belonging to the hybrid peptide/polyketide chlorinated
class of compounds; smenolactones, four chlorinated compounds with a polyketide structure [6]; and
smenopyrone, a biogenetically different compound with a polypropionate structure containing two
γ-pyrone rings [7].
Smenamide A (3) (Figure 1) isolated in 2013 from the Caribbean sponge Smenospongia aurea, showed
potent cytotoxic activity at nanomolar levels on lung cancer Calu-1 cells through an unambiguous
pro-apoptotic mechanism [3].
Although the cytotoxic activity of smenamide A could be determined with only a few micrograms
of the compound, larger amounts were needed to further study the biological activity and to determine
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the configuration at C-16, which remained undetermined until the total synthesis of 16-epi-smenamide
A and ent-smenamide A was accomplished [8]. To further our understanding of the activity-related
structural features of this class of molecules, a series of short derivatives of the 16-epi- series were
designed, prepared, and tested for antiproliferative activity [9]. Recently, the family of smenamide
compounds was further expanded with the isolation of smenamides C, D, and E. Interestingly,
smenamides C (5) and E (7) showed moderate neurotoxicity against neuro-2A cells, while smenamide
D (6), the geometric isomer of 5, did not show any cytotoxic activity [10]. Moreover, it is interesting
to cite a recent publication by Cantrell et al. in which molecular networking in combination with
MS2LDA analysis allowed to describe the intra and inter-chemical diversity present in a S. aurea sample
collected in Florida Keys [11].
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smenamide A (3). Smenamide G (2) only differs from (1) in the configuration at C-8 (the α carbon of 
the putative biosynthetic precursor phenylalanine). Despite the minute amounts isolated, a 
preliminary biological screening was performed on a panel of solid tumour cell lines [MCF-7 (breast 
cancer), MDA-MB-231 (triple negative breast cancer), and MG-63 (osteosarcoma)] to investigate the 
possible antiproliferative activity of the two compounds. 
2. Results and Discussion 
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and Isolation. 
A specimen of S. aurea collected along the coast of Little Inagua (Bahamas Islands) was extracted 
as described in our previous papers [3,4,5,12]. Briefly, the sponge was extracted in sequence with 
MeOH, MeOH/CHCl3 mixtures, and CHCl3. The methanol extract was partitioned between H2O and 
BuOH, and the BuOH layer was combined with the other organic extracts. The crude extract was 
subjected to C-18 reversed-phase column chromatography. The fraction containing chlorinated 
metabolites was partitioned in a two-phase system composed of chloroform, methanol and acidic 
water (1% v/v of acetic acid) to remove the high amounts of brominated alkaloids also present in the 
sponge. The organic phase was analyzed for chlorinated metabolites by LC-HRMS and LC-
HRMS/MS on a LTQ Orbitrap instrument, and the raw analytical data were elaborated and studied 
using molecular networking. Molecular networking is a powerful bioinformatic tool used to speed 
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In this paper, we report on the use of a molecular networking dereplication strategy which
resulted in the rapid detection from extracts of S. aurea of two new members of the smenamide family,
smenamide F (1) and G (2). The new compounds were isolated, their structure elucidated, and their
absolute configuration determined. Smenamide F (1) was shown to be a hydrated analog of smenamide
A (3). Smenamide G (2) only differs from (1) in the configuration at C-8 (the α carbon of the putative
biosynthetic precursor phenylalanine). Despite the minute amounts isolated, a preliminary biological
screening was performed on a panel of solid tumour cell lines [MCF-7 (breast cancer), DA-MB-231
(triple negative breast cancer), and MG-63 (osteosarcoma)] to investigate the possible antiproliferative
activity of the two compounds.
2. Results and Discussion
2.1. Fast Detection of Two New Analogues of the Smenamide Family: Construction of the Molecular Network
and Isolation
A specimen of S. aurea collected along the coast of Little Inagua (Bahamas Islands) was extracted
as described in our previous papers [3–5,12]. Briefly, the sponge was extracted in sequence with
MeOH, MeOH/CHCl3 mixtures, and CHCl3. The methanol extract was partitioned between H2O
and BuOH, and the BuOH layer was combined with the other organic extracts. The crude extract
was subjected to C-18 reversed-phase column chromatography. The fraction containing chlorinated
metabolites was partitioned in a two-phase system composed of chloroform, methanol and acidic water
(1% v/v of acetic acid) to remove the high amounts of brominated alkaloids also present in the sponge.
The organic phase was analyzed for chlorinated metabolites by LC-HRMS and LC-HRMS/MS on a
LTQ Orbitrap instrument, and the raw analytical data were elaborated and studied using molecular
networking. Molecular networking is a powerful bioinformatic tool used to speed up dereplication
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of compounds from the organic extract, leading to the identification of known metabolites as well
as new analogues [13,14]. Specifically, raw LC-MS data were first pre-processed using the mzMine
program [15] to deconvolute chromatographic peaks, distinguish between isomeric compounds based
on their retention times, and remove isotope and adduct peaks, as described in details in our previous
paper [6]. Then, the .mgf MS2 data files were submitted to the Global Natural Product Social Molecular
Network (GNPS) online platform [16], along with the reference MS2 spectra of smenamides C and E [10],
and a molecular network was generated. Finally, the network was visualized using the Cytoscape
program [17]. Two smenamide-related clusters were present in the network and are shown in Figure 2.
Cluster 1 contained smenamide A and B, along with smenamide C and two minor unidentified isomeric
compounds at m/z 487.23 previously detected and described in reference [11]. Cluster 2 contained
smenamide E and three more compounds, smenamides F (1) and G (2), and an unidentified analogue
at m/z 533.28. These nodes were also present in the network reported in [11], although they are not
discussed in the text.
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fragmentation of smenamide. A cluster containing the new smenamides F and G was also present in 
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The new smenamides F and G were isolated by subjecting the chlorinated metabolite fraction to two 
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2.2. Structure Elucidation of Smenamides F and G 
The high-resolution ESI MS spectrum of smenamide F (1) displayed peaks at m/z 519.2620 ([M + 
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of one chlorine atom in the molecule, allowing for the determination of the molecular formula 
C28H39ClN2O5 with 10 unsaturations. The 1H NMR spectrum of smenamide F (1) was indicative of a 
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protons (H-10, δ 4.90 and H-21, δ 5.97), five methyl groups (one acetyl methyl, one N-methyl, one O-
methyl and two aliphatic methyl groups), and a methine proton (H-15, δ 3.99). The general features 
of the spectrum suggested compound 1 to belong to the smenamide family. A second methyl doublet 
(H3-14, δ 1.02) replacing the vinylic methyl singlet of smenamide A (3), the oxymethine group at C-
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Interestingly, although compounds 1–7 all belong to the smenamide family, they are split into two
different clusters, according to the hydration state of the central part of the molecule. Therefore, it
is evident that the hydration of the double bond in position 13 affects in a very significant way the
fragmentation of smenamide. A cluster containing the new smenamides F and G was also present in
the network comparing chlorinated metabolites of S. aurea and the cyanobacterium Trichodesmium sp. [6];
the network showed they were present exclusively (smenamide G) or almost exclusively (smenamide F)
in S. aurea.
The new smenamides F and G were isolated by subjecting the chlorinated metabolite fraction to
two subsequent reversed-phase HPLC separations, which afforded smenamide F (1, 237 µg) and G
(2, 91 µg) as pure compounds.
2.2. Structure Elucidation of Smenamides F and G
The high-resolution ESI MS spectrum of smenamide F (1) displayed peaks at m/z 519.2620
([M + H]+) and 541.2440 ([M + Na]+). Intense (32%) M+2 isotope peaks of both ions suggested the
presence of one chlorine atom in the molecule, allowing for the determination of the molecular formula
C28H39ClN2O5 with 10 unsaturations. The 1H NMR spectrum of smenamide F (1) was indicative of a
mixed NRPS/PKS biogenesis metabolite, in that it showed signals for five aromatic protons, suggesting
a monosubstituted phenyl group, one amino acid α proton (H-8, δ 4.90), two olefinic protons (H-10,
δ 4.90 and H-21, δ 5.97), five methyl groups (one acetyl methyl, one N-methyl, one O-methyl and two
aliphatic methyl groups), and a methine proton (H-15, δ 3.99). The general features of the spectrum
suggested compound 1 to belong to the smenamide family. A second methyl doublet (H3-14, δ 1.02)
replacing the vinylic methyl singlet of smenamide A (3), the oxymethine group at C-15, and one less
unsaturation showed smenamide F (1) to be a hydrated analog of smenamide A (3).
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In the polyketide moiety of the molecule, a moderately deshielded methylene group (H2-22, δ 2.25)
showed a COSY correlation peak with a second methylene group (H2-23, δ 1.71) which was, in turn,
J-coupled with another methylene group (H2-24, δ 3.39). This latter group showed HMBC correlation
peaks with an N-methyl group (CH3-27, δH 3.07, δC 36.7) and a carbonyl carbon (C-25, δC 173.4).
The presence of correlation peaks of the N-methyl group at C-27, and an acetyl methyl group (CH3-26,
δH 2.09, δC 21.8) with the carbonyl carbon atom at δC 173.4, established the N-methylacetamido function
as the western terminus of the molecule. As a result of the E/Z conformational equilibrium at the
N-methylacetamido function, most resonances in the proton NMR spectrum of compound 1 were split
into two signals, with an approximate 1:1 ratio. This is quite common for cyanobacterial metabolites
with a tertiary N-methyl amide function, such as kalkitoxin [18]. The Z conformer was identified from
a strong ROESY correlation peak between H3-26 (δ 2.09) and H3-27 (δ 3.07), whereas the E conformer
showed a correlation peak between H3-26 (δ 2.11) and H2-24 (δ 3.39) (Figure 3). Another deshielded
methylene function (H2-19, δ 2.21) was correlated by COSY to a diasterotopic pair of methylene protons
(Ha-18, δ 1.64; Hb-18, δ 1.45), in turn coupled with the methine H-16 (δ 1.66). The latter showed COSY
correlation peaks with a methyl group (H3-17, δ 0.94) and with the H-15 oxymethine proton at δ 3.99.
Finally, H-15 was coupled with the methine proton H-13 at δ 4.08, in turn coupled with another methyl
group (H3-14, δ 1.02). The HMBC correlation peaks of H2-19 and H2-22 with the methine carbon at
δ 113.8 and the non-protonated carbon at δ 143.7 identified a trisubstituted double bond, linking the
two partial structures defined up to this point. The deshielded chemical shift of H-21, along with the
shielded chemical shift of C-21 (δ 113.8), revealed the presence of a chlorine atom linked to C-21, in
agreement with the molecular formula. The remaining part of the molecule was easily recognized as a
dolapyrrolinone unit based on the similarity of 1H and 13C NMR profiles of smenanamide F (1) with
smenamide A (3), along with the overall HMBC spectral data (Figure 3).
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dinitrophenyl)-L-alaninamide, or L-FDAA]. The resulting L-FDAA derivative was subjected to LC-
ESIMS analysis and showed the same retention time of an authentic standard prepared from L-FDAA 
and L-Phe, thus determining the S configuration at C-8. 
The conformational rigidity of a 1,3-disubstituted alkyl chain (like the C-12/C-18 segment of 
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Figure 3. ost significant correlations provided by the COSY, HMBC, and ROESY 2D NMR spectra of
smenamide F (1).
Smenamide F (1) contains one double bond at C-20/C-21 and four stereogenic centers at C-8 (the
amino acidic α carbon), C-13, C-15, and C-16. The Z configuration at position 20 was determined from
the ROESY correlation peak between H-21 and H2-19 (δ 2.21). The configuration at C-8 was determined
by Marfey’s method [19]. Compound 1 was subjected first to ozolysis to prevent racemization at the α
carbon of the pyrrolidinone-modified amino acid [20], then to hydrolysis with HCl 6 N, and finally to
derivatization with the l enantiomer of Marfey’s reagent [N-(5-fluoro-2,4-dinitrophenyl)-l-alaninamide,
or l-FDAA]. The resulting l-FDAA derivative was subjected to LC-ESIMS analysis and showed the
same retention time of an authentic standard prepared from l-FDAA and l-Phe, thus determining the
S configuration at C-8.
The conformational rigidity of a 1,3-disubstituted alkyl chain (like the C-12/C-18 segment of
compound 1) was the foundation for determining the relative configuration at C-13, C-15, and C-16.
As discussed in our previous work [6], for such a system, only two low-energy conformers may
exist (Figure 4A), because of the unfavorable syn-pentane interactions [21] present in all the other
conformers. In addition, for this system, the expected pattern of couplings between vicinal protons is
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opposite between the two conformers (Figure 4A). Therefore, the large coupling between H-13 and
H-15 and the small coupling between H-15 and H-16 showed that one of the two conformers must be
largely predominant in compound 1 (irrespective of configurations at C-13, C-15, and C-16).
Under these assumptions, the relative configurations at C-13 and C-16 could be determined based
on NOESY data. The two possible diastereomers are depicted in Figure 4B,C. Both conformations are
represented for each diastereomer, while configuration at C-15 is left unassigned for the time being.
It can be easily seen that experimental data, i.e., the strong NOESY correlations of H-13 with H3-17
and H-16 with H3-14 and the absence of any correlation of H-13 with H2-18, could only be accounted
for by conformation d in Figure 4C. This established both the C13/C16 relative configuration and the
conformation of this part of the molecule. On this rigid framework, configuration at C-15 could be
easily determined on the basis of vicinal couplings as shown in Figure 4D. This was confirmed by the
NOESY correlation between the gauche vicinal protons H-15 and H-16, and by the absence of NOE
between the anti-vicinal protons H-13 and H-15. Therefore, the configuration of the polyketide part of
the molecule was assigned as 13S,15S,16R or 13R,15R,16S.
Unfortunately, we were not able to correlate configuration at C-8 with configurations at
C13/C15/C/16. However, with the reasonable hypothesis that smenamide F (1) possesses the same 16R
configuration as smenamide A (3) [8], the absolute stereochemistry of compound 1 can be assumed to
be 8S,13S,15S,16R,20Z.
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The high-resolution ESI mass spectrum of smenamide G (2) showed [M + H]+ and [M + Na]+ ions 
at m/z 519.2620 and 541.2440, respectively, consistent with the molecular formula C28H39ClN2O5, and 
suggesting that it is isomeric with smenamide F (1). The one-dimensional 1H NMR spectrum of 
compound 2 appeared nearly identical to that of compound 1 (including conformational 
equilibrium), with minor differences in chemical shifts for all signals. Correlation peaks in the 2D 
NMR spectra (including NOESY) were also very similar, and the MS/MS fragmentation pattern was 
identical (Figures S3 and S10). These observations led to the conclusion that smenamide F and G were 
stereoisomers. The coupling constants of protons at C-13, C-15, and C-16 were very similar for both 
compounds, suggesting that smenamide G (2) has the same relative configuration as smenamide F 
(1). In contrast, Marfey’s analysis showed that the L-FDAA derivative obtained from compound 2 
was identical to L-FDAA-D-Phe, and therefore, that configuration at C-8 was R. Therefore, smenamide 
( ) e o l t possi l co f r 1, - i
it ethyl groups; (C) Conformation with anti-methyl groups; (D) Configuration of the C-12/C-18
polyketide portion f the molecule.
The high-resolution ESI ass spectrum of smenamide G (2) showed [M + H]+ and [M + Na]+
ions at m/z 519.2620 and 541.2440, respectively, consistent with the molecular formula C28H39ClN2O5,
and suggesting that it is isomeric with smenamide F (1). The one-dimensional 1H R spectru of
co pound 2 appeared nearly identical to that of compound 1 (including conformational equilibrium),
with minor differences in chemical shifts for all signals. Correlation peaks in the 2D NMR spectra
(including NOESY) were also very similar, and the MS/MS fragmentation pattern was identical (Figures
S3 and S10). These observations led to the conclusion that smenamide F and G were stereoisomers.
The coupling constants of protons at C-13, C-15, and C-16 were very similar for both compounds,
suggesting that smenamide G (2) has the same relative configuration as smenamide F (1). In contrast,
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Marfey’s analysis showed that the l-FDAA derivative obtained from compound 2 was identical to
l-FDAA-d-Phe, and therefore, that configuration at C-8 was R. Therefore, smenamide G (2) was
determined as the epimer at C-8 of smenamide F (1), i.e., the 8R,13S,15S,16R,20Z stereoisomer.
To support the stereochemical assignments made so far, the ECD spectra of smenamides F (1) and
G (2) were measured. The ECD spectrum of smenamide F (Figure S1) was similar to that of smenamide
A (3), while the ECD spectrum of smenamide G (Figure S1) was approximately its mirror image.
This data clearly showed that the ECD spectrum of the smenamides is dominated by the chirality of
the dolapyrrolinone moiety, and therefore, cannot provide information on the configuration of the
polyketide part of the molecule.
2.3. Antiproliferative Activity of Smenamides F and G
Preliminary screening of antiproliferative activity of smenamide F and G was performed on three
different solid tumor lines, namely MCF-7 (breast cancer), MDA-MB-231 (triple negative breast cancer)
and MG-63 (osteosarcoma) cell lines. Smenamides F and G were evaluated individually against cancer
cells at concentrations of 1 and 5 µM for 96 h. As previously reported [6], cell growth was monitored
in real-time by using the xCELLigence System Real-Time Cell Analyzer (RTCA), which translates
electronic impedance variations into cell index (CI) data, a closely related parameter to cell viability
and morphology. At the lowest dose (1 µM) of each compound, cell proliferation was unaffected or
only slightly delayed after drug treatment in all three models. At 5 µM concentration, smenamide F (1)
and G (2) were shown to exert selective moderate antiproliferative activity against both MCF-7 and
MDA-MB-231 breast carcinoma cell lines (Figure 5), while being inactive against osteosarcoma cells
(Figure 6). Indeed, smenamides prompted a) significant reduction in the slope of the growth curve
(within the range of 30–40%) and b) significant delay in cell doubling time exclusively in breast models
at the highest dose (5 µM). Moreover, the absolute configuration at C-8 of the dolapyrrolinone unit
does not affect growth inhibitory properties of compounds in the tested cell lines.
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3. Materials and Methods
3.1. General Experimental Procedures
High-resolution ESI-MS and HR-ESI-MS-HPLC experiments were performed on a Thermo LTQ
Orbitrap XL mass spectrometer (Thermo Fisher Scientific Spa, Rodano, Italy) coupled to an Agilent
model 1100 LC system (Agilent Technology Cernusco sul Naviglio, Italia). The spectra were recorded
by infusion into the ESI source using MeOH as the solvent. CD spectra were recorded using a Jasco
J-710 (Easton, MD) spectrophotometer using a 1 mm cell. NMR experiments were performed on Varian
Unity Inova spectrometers (Agilent Technology Cernusco sul Naviglio, Italia) at 700 MHz in CD3OD;
chemical shifts were referenced to the residual solvent signal (CD3OD: δH 3.31, δC 49.00). All 13C
chemical shift were assigned using the 2D spectra, therefore, mono-dimensional 13C NMR spectra
were not recorded (see Tables S1 and S2). For an accurate measurement of the coupling constants,
the one-dimensional 1H NMR spectra were transformed at 64 K points (digital resolution: 0.09 Hz).
Through-space 1H connectivities were evidenced using a ROESY experiment with a mixing time
of 450 ms. The HSQC spectra were optimized for 1JCH = 142 Hz and the HMBC experiments for
2,3JCH = 8.3 Hz. High-performance liquid chromatography (HPLC) separations were achieved on a
Varian Prostar 210 apparatus equipped with a Varian Prostar 325 UV-Vis detector.
3.2. Collection, Extraction and Isolation
A specimen of Smenospongia aurea was collected by scuba along the southwest coast of Little Inagua
(Bahamas Islands) on 9 July 2013 on a research expedition using the R/V Walton Smith. After collection,
the sample was identified onboard following the information reported on the website The Sponge
Guide [22], immediately frozen and stored at −20 ◦C until extraction. The sponge (712 g wet weight)
was homogenized and extracted with MeOH (4 × 4 L), MeOH and CHCl3 in different ratios (2:1, 1:1,
1:2) and then with CHCl3 (2 × 4 L). The MeOH extract was partitioned between H2O and n-BuOH; the
BuOH layer was combined with the CHCl3 extracts and concentrated in vacuo.
The resulting organic extract (16.31 g) was subjected to reversed-phase chromatography using
a column packed with RP-18 silica gel. The fraction eluted with MeOH/H2O (9:1) (363.7 mg) was
partitioned in a two-phase system composed by H2O (160 mL), MeOH (260 mL), CHCl3 (140 mL)
and AcOH (5 mL). The organic layer, containing smenamides, was subjected to reversed-phase HPLC
separation (column 250 × 10 mm, 10 µm, Luna (Phenomenex) C18; Eluent A: H2O; Eluent B: MeOH;
gradient: 55%→ 100% B over 60 min, flow rate 5 mL/min), thus affording a fraction (tR = 27.5 min)
containing Compound 1 and a fraction (tR = 28.5 min) containing Compound 2. The two fractions
were each separated on reversed-phase HPLC (column 250 × 4.6 mm, 5 µm, Luna (Phenomenex) C18;
Eluent A: H2O; Eluent B: ACN; gradient: 50%→100% B, over 35 min, flow rate 1 mL·min−1), which
gave 237 µg of pure compound 1 (tR =14.0 min) and 91 µg of pure compound 2 (tR = 14.5 min).
3.2.1. Smenamide F (1)
Colorless amorphous solid, HRESIMS (positive ion mode, MeOH) m/z 541.2443 ([M + Na]+,
C28H39ClN2O5 calcd. 541.2445); MS isotope pattern: M (100%), M + 1 (30%, calcd. 30.9%),
M + 2 (34%, calcd. 32%); HRESIMS/MS (parent ion m/z 541.2443, C28H39ClN2NaO5+): m/z 523.2332
(C28H37ClN2NaO4+, calcd. 523.2334), m/z 294.1600 (C15H26ClNNaO+, calcd. 294.1595), m/z 282.1252
(C13H22ClNNaO2+, calcd. 282.1231).
1H and 13C NMR: Supplementary Table S1. CD (MeOH): λmax 229 (+18.3).
3.2.2. Smenamide G (2)
Colorless amorphous solid, HRESIMS (positive ion mode, MeOH) m/z 541.2440 ([M + Na]+,
C28H39ClN2O5 calcd. 541.2445); MS isotope pattern: M (100%), M + 1 (30%, calcd. 30.9%),
M + 2 (34%, calcd. 32%); HRESIMS/MS (parent ion m/z 541.2443, C28H39ClN2NaO5+): m/z 523.2338
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(C28H37ClN2NaO4+, calcd. 523.2334), m/z 294.1610 (C15H26ClNNaO+, calcd. 294.1595), m/z 282.1249
(C13H22ClNNaO2+, calcd. 282.1231).
1H and 13C NMR: Supplementary Table S2. CD (MeOH): λmax 228 (−6.9).
3.3. Determination of the Absolute Configuration of the Amino Acids
3.3.1. Ozonolysis and Hydrolysis
A small amount of compound 1 (5 µg) and 2 (5 µg) were separately suspended in ozone-saturated
MeOH (300 µL) at −78 ◦C for 5 min. The samples were dried under a N2 stream to remove the ozone,
then treated with 6 N HCl and heated in a flame-sealed glass tube at 180 ◦C for 2 h. The residual HCl
fumes were removed in vacuo.
3.3.2. Marfey’s Derivatization with D- and L-FDAA
The hydrolysate of 1 was dissolved in triethylamine/ACN (2:3) (80 µL), and this solution was then
treated with 1% 1-fluoro-2,4-dinitrophenyl-5-l-alaninamide (l-FDAA) in ACN/acetone (1:2) (75 µL). The
vial was heated at 50 ◦C for 1 h. The mixture was dried and resuspended in ACN/H2O (5:95) (500 µL)
for subsequent LC-MS analysis (I). The hydrolysate of 2 was treated with d-FDAA under identical
conditions as 1 (II). Authentic l-Phe standard was treated with l-FDAA and d-FDAA as above (III).
3.3.3. LC-MS Analysis
The Marfey’s derivatives were analyzed by HR-ESI-MS-HPLC. A 5 µm Kinetex C18 column
(100 × 2.10 mm), maintained at room temperature, was eluted at 250 µL·min−1 with H2O and ACN,
using a gradient elution. The gradient program was the following: 5% ACN 3 min, 5–60% ACN over
20 min, 90% ACN 5 min. Mass spectra were acquired in positive ion detection mode, and the data were
analyzed using the suite of programs, Xcalibur. The retention times of the Marfey’s derivatives (I), (II)
and (III) were the following, tR = (l/d) in min: phenilalanine (m/z 418.1357, [M + H]+) tR = 17.32/18.60;
l-FDAA-Phe from 1 tR = 17.68; l-FDAA-Phe from 2 tR = 18.63.
3.4. Molecular Network
A molecular network [14] was generated using the online workflow at GNPS (https://gnps.ucsd.
edu/). The parent mass tolerance and MS/MS fragment ion tolerance were both set at 0.02 Da. In the
resulting molecular network, edges were refined to have a cosine score above 0.6 and more than six
matched peaks. The spectra in the network were then compared with those in GNPS spectral libraries.
To observe a matching between network spectra and library spectra, a cosine score above 0.7 and
at least six matched peaks were required. Once the basic molecular network was generated, it was
visualized with Cytoscape 3.2.122 [15].
3.5. Cell Culture
MCF-7, MDA-MB-231 and MG-63 cells were purchased from American Type Culture Collection
(ATCC, Manassas, VA, USA). MCF-7, MDA-MB-231 and MG-63 cells were cultured in DMEM medium
at 37 ◦C in a 5% CO2 humidified atmosphere. DMEM medium was supplemented with 10% fetal bovine
serum, penicillin–streptomycin (100 U/mL), and 2 mM L-glutamine. Cell morphology was observed
using an inverted optical microscope (Axio Vert A1, Zeiss, Oberkochen, Germany). When cells reached
the confluence, cells were detached with 0.05% trypsin-EDTA to perform xCELLIgence assays.
3.6. xCELLigence Assays and Statistical Analysis
The xCELLigence System Real-Time Cell Analyzer (ACEA Biosciences, San Diego, CA, USA)
was used for monitoring proliferation of cancer cells. Antiproliferative assays were performed as
previously described [6]. MCF7 and MDA-MB-231 cells were seeded at a cell density of 3000 cells/well
while MG-63 cells were seeded at a cell density of 4000 cells/well. Approximately 24 h after seeding,
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medium was removed, and cells were treated with medium containing either 1 or 5 µM concentrations
of each compound for 96 h.
For our data analysis, CI was normalized just before drug treatment and converted into a
normalized cell index (NCI). Normalized cell index was calculated as follows: NCI = CI end of treatment/
CI normalization time. Real-time NCI traces were produced by the RTCA-integrated software.
Antiproliferative effects of smenamides are presented either as cell index slopes relative to controls
treated with DMSO vehicle or as cell doubling times. Cell index slopes and doubling times were
calculated using the RTCA-integrated software. The NCI slope describes the rate of change of the cell
index for cells after treatment with a cytotoxic compound. Doubling time is the time required for a
curve cell index value to double. Data are presented as mean ± standard deviation (n = 3). Differences
between groups were determined by analysis of variance (ANOVA) to determine statistical significance,
which is reported as p value. The Dunnett’s Multiple Comparison Test was used to compare treatments
with controls. Statistical analysis was performed using the GraphPad Prism Software Version 5.
4. Conclusions
The use of molecular networking as a dereplication strategy allowed for the rapid detection of
two new members of the smenamide family of compounds, smenamide F (1) and G (2). A preliminary
biological screening was performed on three solid tumor cell lines [MCF-7 (breast cancer), MDA-MB-231
(triple negative breast cancer) and MG-63 (osteosarcoma)] to evaluate the possible antiproliferative
activity of the compounds. Data obtained showed that smenamide F (1) and G (2) exert a selective
moderate antiproliferative activity against both breast carcinoma cell lines (MCF-7 and MDA-MB-231)
at 5 µM, while being inactive against the MG-63 osteosarcoma cell line.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/17/11/618/s1,
Table S1: NMR data of smenamide F (1) (CD3OD); Table S2: NMR data of smenamide G (2) (CD3OD); Figure S1:
ECD spectra of smenamide A, smenamide F (1) and G (2); Figure S2: Positive ion mode high-resolution ESI mass
spectrum of smenamide F (1); Figure S3: Positive ion mode high-resolution ESI MS/MS spectrum of smenamide
F (1); Figure S4: 1H-NMR spectrum of smenamide F (1) (700 MHz, CD3OD); Figure S5: COSY spectrum of
smenamide F (1) (700 MHz, CD3OD); Figure S6: NOESY spectrum of smenamide F (1) (700 MHz, CD3OD); Figure
S7: HSQC spectrum of smenamide F (1) (700 MHz, CD3OD); Figure S8: HMBC spectrum of smenamide F (1)
(700 MHz, CD3OD); Figure S9: Positive ion mode high-resolution ESI mass spectrum of smenamide G (2); Figure
S10: Positive ion mode high-resolution ESI MS/MS spectrum of smenamide G (2); Figure S11: 1H-NMR spectrum
of smenamide G (2) (700 MHz, CD3OD); Figure S12: COSY spectrum of smenamide G (2) (700 MHz, CD3OD);
Figure S13: ROESY spectrum of smenamide G (1) (700 MHz, CD3OD); Figure S14: HSQC spectrum of smenamide
G (2) (700 MHz, CD3OD); Figure S15: HMBC spectrum of smenamide G (2) (700 MHz, CD3OD).
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